



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hypoglycemics - Incretin Mimetics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is the requested medication prescribed for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication, excluding use to treat obesity?

Yes No

Q2. Is this a request for a glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase-4 (DPP-4) inhibitor?

Yes No

Q3. Does the patient have a documented history of a failure to achieve glycemic control using maximum tolerated doses of metformin, as evidenced by the patient's hemoglobin A1c (HbA1c) values?

Yes No

Q4. Does the patient have a documented history of a contraindication to or intolerance of metformin?

Yes No

Q5. Does the patient require initial dual therapy with metformin based on HbA1c as defined by the American Diabetes Association or the American Association of Clinical Endocrinologists and American College of Endocrinology?

Yes No

Q6. For a GLP-1 receptor agonist or DPP-4 inhibitor with proven cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) benefit, does the patient have CVD (or two risk factors for CVD as identified by the American Diabetes Association or the American Association of Clinical Endocrinologists and American College of Endocrinology), HF, or CKD?

Yes No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS  
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hypoglycemics - Incretin Mimetics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q7. Is this a request for an amylin analog?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q8. Is this a request for a renewal of authorization for an amylin analog?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Is this a request for an incretin mimetic/enhancer when there is a paid claim for another incretin mimetic/enhancer (i.e., potential therapeutic duplication)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Is the patient being transitioned to or from another incretin mimetic/enhancer with the intent of discontinuing one of the medications?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Has the prescriber provided a medical reason for concomitant use of the requested medications that is supported by peer-reviewed literature or national treatment guidelines?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Does the patient have improved glycemic control, as evidenced by a recent hemoglobin A1c (HbA1c) value?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Does the patient have a diagnosis of type 1 diabetes mellitus?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Does the patient have a diagnosis of type 2 diabetes mellitus?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Does the patient have a documented history of a failure to achieve glycemic control using maximum tolerated doses of metformin, as evidenced by the patient's hemoglobin A1c (HbA1c) values?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Does the patient have a documented history of a contraindication to or intolerance of metformin?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Has the patient failed to achieve adequate glycemic control despite compliance with optimal insulin therapy, as evidenced by the beneficiary's hemoglobin A1c (HbA1c) values?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Will the requested amylin analog be prescribed in combination with insulin?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS  
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hypoglycemics - Incretin Mimetics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q19. Is this a request for an incretin mimetic/enhancer when there is a paid claim for another incretin mimetic/enhancer (i.e., potential therapeutic duplication)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Is the patient being transitioned to or from another incretin mimetic/enhancer with the intent of discontinuing one of the medications?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q21. Has the prescriber provided a medical reason for concomitant use of the requested medications that is supported by peer-reviewed literature or national treatment guidelines?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q22. Is this a request for a preferred incretin mimetic/enhancer drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q23. Does the patient have a documented history of therapeutic failure, contraindication to, or intolerance of the preferred incretin mimetic/enhancer drugs with the same mechanism of action as the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q24. Additional Information:</p>

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

*Updated for 2021*